Akebia Therapeutics Inc <AKBA.OQ> expected to post a loss of 2 cents a share - Earnings Preview
Akebia Therapeutics Inc AKBA.OQ AKBA.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Cambridge Massachusetts-based company is expected to report a 8.2% increase in revenue to $47.237 million from $43.65 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Akebia Therapeutics Inc is for a loss of 2 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 46.3% above its last closing price of $3.76
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.03 | -0.04 | 0.03 | Beat | 166.7 |
Dec. 31 2025 | -0.09 | -0.08 | -0.10 | Missed | -25 |
Sep. 30 2024 | -0.07 | -0.06 | -0.10 | Missed | -57.9 |
Jun. 30 2024 | -0.05 | -0.05 | -0.04 | Beat | 25 |
Mar. 31 2024 | -0.08 | -0.08 | -0.09 | Missed | -17.4 |
Dec. 31 2023 | -0.04 | -0.04 | 0.00 | Beat | 100 |
Sep. 30 2023 | -0.07 | -0.08 | -0.08 | Met | 5.9 |
Jun. 30 2023 | -0.02 | -0.02 | -0.06 | Missed | -140 |
This summary was machine generated August 5 at 13:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
